Kohlberg Kravis Roberts & Co’s Coherus Oncology CHRS Stock Holding History

Kohlberg Kravis Roberts & Co’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.07M	Hold	3,036,076	–	–	0.09%	25
2025 Q4	$4.25M	Hold	3,036,076	–	–	0.07%	29
2025 Q3	$4.93M	Hold	3,036,076	–	–	0.08%	29
2025 Q2	$2.17M	Hold	3,036,076	–	–	0.04%	33
2025 Q1	$2.41M	Hold	3,036,076	–	–	0.05%	35
2024 Q4	$4.15M	Hold	3,036,076	–	–	0.11%	28
2024 Q3	$3.12M	Hold	3,036,076	–	–	0.04%	38
2024 Q2	$5.25M	Hold	3,036,076	–	–	0.16%	32
2024 Q1	$7.26M	Hold	3,036,076	–	–	0.19%	27
2023 Q4	$10.1M	Hold	3,036,076	–	–	0.3%	27
2023 Q3	$11.4M	Hold	3,036,076	–	–	0.4%	25
2023 Q2	$13M	Hold	3,036,076	–	–	0.4%	23
2023 Q1	$20.8M	Hold	3,036,076	–	–	0.63%	19
2022 Q4	$24M	Hold	3,036,076	–	–	0.81%	18
2022 Q3	$29.2M	Hold	3,036,076	–	–	0.59%	17
2022 Q2	$22.6M	Hold	3,036,076	–	–	0.3%	22
2022 Q1	$39.2M	Hold	3,036,076	–	–	0.36%	18
2021 Q4	$48.5M	Hold	3,036,076	–	–	0.27%	15
2021 Q3	$48.8M	Hold	3,036,076	–	–	0.24%	19
2021 Q2	$42M	Hold	3,036,076	–	–	0.17%	23
2021 Q1	$44.4M	Hold	3,036,076	–	–	0.22%	24
2020 Q4	$52.8M	Hold	3,036,076	–	–	0.27%	26
2020 Q3	$55.7M	Hold	3,036,076	–	–	0.32%	24
2020 Q2	$54.2M	Hold	3,036,076	–	–	0.33%	17
2020 Q1	$49.2M	Sell	3,036,076 -18,979	-0.6%	-$351K	0.31%	14
2019 Q4	$55M	Hold	3,055,055	–	–	0.27%	18
2019 Q3	$61.9M	Hold	3,055,055	–	–	0.35%	16
2019 Q2	$67.5M	Hold	3,055,055	–	–	0.83%	16
2019 Q1	$41.7M	Hold	3,055,055	–	–	0.63%	18
2018 Q4	$27.6M	Hold	3,055,055	–	–	0.5%	24
2018 Q3	$50.4M	Hold	3,055,055	–	–	0.57%	22
2018 Q2	$42.8M	Hold	3,055,055	–	–	0.49%	19
2018 Q1	$33.8M	Hold	3,055,055	–	–	0.41%	17
2017 Q4	$26.9M	Hold	3,055,055	–	–	0.26%	28
2017 Q3	$40.8M	Hold	3,055,055	–	–	0.47%	22
2017 Q2	$43.8M	Hold	3,055,055	–	–	0.5%	19
2017 Q1	$64.6M	Hold	3,055,055	–	–	1.16%	11
2016 Q4	$86M	Hold	3,055,055	–	–	1.37%	9
2016 Q3	$81.8M	Hold	3,055,055	–	–	1.02%	10
2016 Q2	$51.6M	Buy	+3,055,055	New	+$57.4M	0.54%	20
2015 Q1	–	Sell	-3,055,055	Closed	-$49.9M	–	93
2014 Q4	$49.9M	Buy	+3,055,055	New	+$43.1M	0.65%	10

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Kohlberg Kravis Roberts & Co's CHRS Position: Q1 2026 in Review

Kohlberg Kravis Roberts & Co held its Coherus Oncology (CHRS) position steady in Q1 2026 at 3,036,076 shares worth $5.07M. The position accounts for 0.09% of the portfolio, ranked #25.

Kohlberg Kravis Roberts & Co first reported a position in CHRS in Q4 2014 and has held it in 41 quarters since. The position peaked at $86M in Q4 2016. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

Kohlberg Kravis Roberts & Co held 3,036,076 shares of Coherus Oncology worth $5.07M as of Q1 2026.
Kohlberg Kravis Roberts & Co left its Coherus Oncology share count unchanged in Q1 2026.
Coherus Oncology made up 0.09% of Kohlberg Kravis Roberts & Co's portfolio in Q1 2026, its #25 holding.
Kohlberg Kravis Roberts & Co first reported a position in Coherus Oncology in Q4 2014 and has held it in 41 quarters since.
Kohlberg Kravis Roberts & Co's Coherus Oncology position peaked at $86M in Q4 2016.
157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on Kohlberg Kravis Roberts & Co's 13F filing for Q1 2026, filed 15 May 2026.